Omnicell, Inc. (NASDAQ:OMCL) Given Consensus Rating of “Moderate Buy” by Brokerages

Omnicell, Inc. (NASDAQ:OMCL) has been given a consensus rating of “Moderate Buy” by the nine ratings firms that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $59.8571.

Several research firms recently weighed in on OMCL. Craig Hallum restated a “buy” rating and set a $55.00 target price on shares of Omnicell in a research note on Wednesday, April 29th. Wells Fargo & Company increased their price target on shares of Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a research note on Thursday, April 23rd. Zacks Research cut shares of Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. KeyCorp boosted their price objective on shares of Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 28th. Finally, Weiss Ratings upgraded shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th.

Omnicell Price Performance

Omnicell stock opened at $41.00 on Monday. The stock has a market cap of $1.86 billion, a PE ratio of 93.18, a P/E/G ratio of 1.06 and a beta of 0.96. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.50 and a quick ratio of 1.29. The stock’s fifty day moving average is $42.40 and its two-hundred day moving average is $41.37. Omnicell has a 1-year low of $27.77 and a 1-year high of $55.00.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The business had revenue of $309.88 million during the quarter, compared to analysts’ expectations of $304.02 million. During the same period in the prior year, the firm posted $0.26 EPS. The business’s quarterly revenue was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. On average, sell-side analysts expect that Omnicell will post 1.31 EPS for the current fiscal year.

Insiders Place Their Bets

In other Omnicell news, EVP Corey J. Manley sold 5,025 shares of the firm’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $217,180.50. Following the transaction, the executive vice president owned 112,783 shares of the company’s stock, valued at approximately $4,874,481.26. This trade represents a 4.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of Omnicell stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $133,549.80. Following the sale, the executive vice president owned 154,785 shares in the company, valued at $6,689,807.70. This trade represents a 1.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is owned by insiders.

Institutional Trading of Omnicell

A number of large investors have recently made changes to their positions in OMCL. Raymond James Financial Inc. purchased a new position in Omnicell during the 2nd quarter worth approximately $26,000. Versant Capital Management Inc lifted its stake in Omnicell by 38.7% in the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock valued at $44,000 after buying an additional 294 shares during the last quarter. Clearstead Advisors LLC boosted its holdings in shares of Omnicell by 12,180.0% in the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after acquiring an additional 1,218 shares during the period. Kemnay Advisory Services Inc. acquired a new stake in shares of Omnicell in the fourth quarter valued at approximately $58,000. Finally, Parkside Financial Bank & Trust grew its position in shares of Omnicell by 1,708.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock worth $61,000 after acquiring an additional 1,264 shares during the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.